Wavefront-guided LASIK with the NIDEK NAVEX platform for the correction of myopia and myopic astigmatism with 6-month follow-up.
To assess safety, efficacy, predictability, stability, and change in higher order aberrations after wavefront-guided LASIK for myopia and myopic astigmatism using the NIDEK NAVEX platform. Wavefront-guided LASIK was performed in 93 eyes in a 6-month trial with a goal of emmetropia. Treated eyes had a mean subjective manifest spherical equivalent refraction of -4.08+/-1.99 D diopters (D), with a range of -9.50 to -0.38 D of myopia and -4.50 to 0.00 D of astigmatism. An early nomogram with the OPDCAT software program provided by the manufacturer was used in all procedures. Safety, efficacy, predictability, stability, and change in higher order aberrations were evaluated at 6 months. At 6 months, 100% eyes were within +/-1.0 D of emmetropia and 95% eyes were within +/-0.5 D. Uncorrected visual acuity (UCVA) of > or = 1.0 was achieved in 89% of eyes, and 38% of eyes achieved UVCA of > or = 1.2. No eyes lost > or = 2 lines of best spectacle-corrected visual acuity (BSCVA), 25% of eyes gained 1 line, 3% gained 2 lines, and 1% gained > or = 2 lines of BSCVA. Higher order root-mean-square (RMS) values increased by 19% on average between pre- and postoperative measurements. Eyes treated with higher order aberrations of < 0.3 RMS showed on average an increase of 40% on preoperative values, whereas eyes with significant aberrations showed a decrease in aberrations following wavefront treatment. Wavefront-guided ablation using the NIDEK NAVEX platform is safe, effective, and predictable. However, patients with low amounts of aberrations showed an increase in aberrations following wavefront treatment, therefore, wavefront treatment may not be indicated or beneficial to every patient.